Table 1 Summary of treatment outcome for cancer pets receiving electrochemotherapy
Drug | Species | N° of patients | Tumor Type | Response | References |
|---|---|---|---|---|---|
B | Cats | 12 | STS | SD 7 months | 18 |
B | Dogs and cats | 16 | Various | 80% CR+PR | 19 |
CDDP | Dogs and cats | 7 | Various | 84% CR | 23 |
B | Dogs and cats | 5 | Various | CR > 24 mo | 25 |
B | Cats | 58 | STS | Median time to recurrence: 12–19 mo | 26 |
B | Dogs | 22 | STS | Median time to recurrence 24 mo | 27 |
B | Dogs | 28 | MCT | 82%CR > 22 mo | 28 |
B | Cats | 9 | SCC | 78%CR> 3 mo | 29 |
B | Cats | 1 | Ganglioneuroblastoma | CR > 15 mo | 30 |
B | Dogs | 10 | Melanoma | 70% CR> 6 mo | 34 |
CDDP | Dogs | 1 | Anal Melanoma | PR 3 mo | 35 |
B | Dogs | 12 | Perianal tumors | 83% CR | 36 |
B | Dogs and Cats | 6 | Lymphoma | 100% CR 1 wk to 36 mo | 37 |
B | Cats | 1 | HPC | CR> 12 mo | 39 |
CDDP | Dogs | 1 | Anal sac carcinoma | CR> 18 mo | 40 |
CDDP | Cats | 1 | Fibrosarcoma | CR 3 mo | 41 |
Mitoxantrone | Dogs | 1 | Metastatic carcinoma | CR > 6 mo | 43 |